RVMD Stock Recent News

The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO Steve Kelsey - President of Research & Development Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Ami Fadia - Needham Alec Stranahan - Bank of America Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2023 Earnings Conference Call.

Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.87 per share a year ago.

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancreatic cancer. High numbers of unconfirmed responses caused investors to be disappointed with the results.

Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Revolution Medicines is a clinical-stage biotech. The company has nearly a million in cash to develop its deep pipeline.

Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor)

Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The company is focusing on developing RAS(ON) inhibitors, which target the active form of KRAS, with several promising candidates in development. Revolution Medicines has a strong financial position with almost $2 billion in cash, but its current valuation may not be justified without meaningful clinical data.

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relations Mark Goldsmith – Chairman and Chief Executive Officer Jack Anders – Chief Financial Officer Steve Kelsey – President of Research & Development Conference Call Participants Marc Frahm – TD Cowen Faisal Khushid – Leerink Partners Jay Olson – Oppenheimer Ami Fadia – Needham Alec Stranahan – Bank of America Ben Burnett – Stifel Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Second Quarter 2023 Earnings Conference Call.